(Q33599155)

28 July 2017

Evaluation of the exposure equivalence of oral versus intravenous temozolomide (English)

1 reference

28 July 2017

0 references

Blanca D Diez

1

1 reference

28 July 2017

Paul Statkevich

2

1 reference

28 July 2017

Yali Zhu

3

1 reference

28 July 2017

Malaz A Abutarif

4

1 reference

28 July 2017

Fengjuan Xuan

5

1 reference

28 July 2017

Bhavna Kantesaria

6

1 reference

28 July 2017

David Cutler

7

1 reference

28 July 2017

Marc Cantillon

8

1 reference

28 July 2017

Max Schwarz

9

1 reference

28 July 2017

Maria Guadalupe Pallotta

10

1 reference

28 July 2017

Fabio H Ottaviano

11

1 reference

28 July 2017

30 July 2009

1 reference

Cancer Chemotherapy and Pharmacology

28 July 2017

1 reference

28 July 2017

65

1 reference

28 July 2017

4

1 reference

28 July 2017

727-734

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-009-1078-6

28 July 2017

0 references

cites work

Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808524

Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808524

Population pharmacokinetics of temozolomide in cancer patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808524

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808524

Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808524

Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808524

Phase I trial of temozolomide using an extended continuous oral schedule.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808524

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808524

Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808524

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808524

Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808524

Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808524

Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808524

Disposition and pharmacokinetics of temozolomide in rat.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808524

Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808524

Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808524

Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19641919

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00280-009-1078-6

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference